Filtering

P389: Low-dose metronidazole is associated with a decreased rate of endoscopic recurrence of Crohn's disease after ileal resectionECCO '17 Barcelona
Year: 2017
Authors:

Glick L.*1, Sossenheimer P.H.1, Hirsch A.1, Hurst R.D.2, Cohen R.D.1, Hyman N.2, Rubin D.T.1

1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States 2University of Chicago Medicine, Department of Surgery, Chicago, United States

P390: Open-label study to evaluate the pharmacokinetics of fidaxomicin in inflammatory bowel disease patients with Clostridium difficile infection (the PROFILE study): pharmacokinetics analysisECCO '17 Barcelona
Year: 2017
Authors:

Högenauer C.1, Mahida Y.2, Stallmach A.3, Marteau P.4, Rydzewska G.5, Ivashkin V.6, Gargalianos-Kakolyris P.7, Michon I.8, Adomakoh N.9, Reinisch W.*10

1Medical University of Graz, Graz, Austria 2University of Nottingham, Nottingham, United Kingdom 3Jena University Hospital, Jena, Germany 4Hôpital Saint Antoine, Paris, France 5Central Clinical Hospital of the Ministry of the Interior, Warsaw and Jan Kochanowski University, Kielce, Poland 6'First Moscow State Medical University named after I.M. Sechenov' of the Ministry of Health of Russian Federation, Moscow, Russian Federation 7General Hospital of Athens “G. Gennimatas”, Athens, Greece 8Astellas Pharma Europe, Leiden, Netherlands 9Astellas Pharma, Chertsey, United Kingdom 10Medical University of Vienna, Vienna, Austria

P391: Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United KingdomECCO '17 Barcelona
Year: 2017
Authors:

Kamperidis N.*1, Cavazza A.2, Wahed M.2, Arebi N.1

1St Mark's Hospital, London, United Kingdom 2Chelsea and Westminster Hospital, Gastroenterology, London, United Kingdom

P392: Comparison of dietary nutrient and food additive intake between patients with moderately active ulcerative colitis, healthy stool donors and the general Australian populationECCO '17 Barcelona
Year: 2017
Authors:

Costello S.*1,2,3, Mashei C.3, Bryant R.2,3, Katsikeros R.3, Waters O.4, Makanyanga J.4, Hughes P.2, Conlon M.5, Roberts-Thomson I.1,2, Andrews J.2,3

1The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia 2University of Adelaide, School of Medicine, Adelaide, Australia 3The Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia 4Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia 5CSIRO, Health and Biosecurity, Adelaide, Australia

P393: Evaluation of pharmacokinetic profiles of SB2 as a biosimilar of reference infliximabECCO '17 Barcelona
Year: 2017
Authors:

Shin D., Kang J.W., Park S., Lee Y., Lee S.

Samsung Bioepis Co., Ltd., Incheon, South Korea

P394: Prolonged azathioprine treatment reduces the need for surgery in early Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Qiu Y.*1, Mao R.1, Zhang S.-h.2, Feng R.2, Zeng Z.-r.1, Chen M.-h.2

1The first affiliated hospital of Sun-yat Sen University, Gastroenterology, Guangzhou, China 2The first affiliated hospital of Sun-yat Sen University, Guangzhou, China

P395: Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)ECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Schreiber S.2, Tang M.T.3, Tatro A.R.3, Oh Y.S.*3, Maciuca R.3

1University of California, San Diego, La Jolla, United States 2Kiel University, Kiel, Germany 3Genentech, South San Francisco, United States

P396: Long-term efficacy of thiopurines as maintenance treatment in 130 patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Lefevre C., Fotsing G., Wangermez M., Beau P.

CHU Poitiers, Poitiers, France

P397: Approach and management of psychological aspects of inflammatory bowel disease described by patients and physicians in Spain. The ENMENTE ProjectECCO '17 Barcelona
Year: 2017
Authors:

Marín-Jiménez I.*1, Panadero A.2, Gobbo Montoya M.3, Cañas M.4, Modino Y.5, Guardiola J.6, Cea-Calvo L.7, Juliá B.7, Romero C.7, Carmona L.8, Barreiro-de Acosta M.9

1Hospital Gregorio Marañόn, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato digestivo e Instituto de Investigaciόn Sanitaria Gregorio Marañόn (IiSGM), Madrid, Spain 2Asociaciόn de Enfermos de Crohn y Colitis Ulcerosa de Madrid (ACCU Madrid), Psicόlogo especializado en Enfermedad Inflamatoria Intestinal, Madrid, Spain 3Positivamente, Centro de Psicología, Madrid, Spain 4Hospital Clínico San Carlos, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Madrid, Spain 5Confederaciόn de Asociaciones de pacientes de enfermos de Crohn y Colitis Ulcerosa de España (ACCU España), Madrid, Spain 6Hospital Universitari de Bellvitge-IDIBELL, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, L'Hospitalet de Llobregat, Barcelona, Spain 7Merck Sharp & Dohme de España, Medical Affairs, Madrid, Spain 8Instituto de Salud Musculoesquelética, InMusc, Madrid, Spain 9Complexo Universitario de Santiago de Compostela, Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Santiago de Compostela, Spain

P398: An objective measure of response to treatment for patients with Crohn's perianal fistulas on anti-TNF treatmentECCO '17 Barcelona
Year: 2017
Authors:

Sahnan K.*1, Lung P.F.2, Adegbola S.O.1, Burling D.2, Burn J.2, Tozer P.J.1, Gupta A.2, Faiz O.D.1, Phillips R.K.1, Hart A.L.3

1St Mark's Hospital, Colorectal Surgery, London, United Kingdom 2St Mark's Hospital, Gastrointestinal Imaging, London, United Kingdom 3St Mark's Hospital, IBD/Physiology, London, United Kingdom

P399: Adverse events associated with azathioprine treatment in Korean pediatric inflammatory bowel disease patientsECCO '17 Barcelona
Year: 2017
Authors:

Kim M.

Inje University College of Medicine, Ilsan Paik Hospital, Pediatrics, Goyang-si, Gyeonggi-do, South Korea

P400: Risk-adjusted use of thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resectionECCO '17 Barcelona
Year: 2017
Authors:

Guo J.1, Mao R.1, Luo X.1, Ben Horin S.1,2, Chen M.*3

1The first affiliated hospital of Sun Yat-Sen University, Department of Radiology, Guangzhou, China 2Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel 3The first affiliated hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China

P401: Anti-TNF treatments in Crohn's disease and improvement in work productivity and quality of life: an observational study from TurkeyECCO '17 Barcelona
Year: 2017
Authors:

Törüner M.*1, Başaranoğlu M.2, Atuğ Ö.3, Şentürk Ö.4, Akyüz F.5, Ünsal B.6, Över Hamzaoğlu H.7, Tekin F.8, Sezgin O.9, Akpınar H.10, Çelik A.F.11, Tezel A.12, Göktürk H.S.13, Kav T.14

1Ankara University School of Medicine, Gastroenterology, Ankara, Turkey 2Bezmialem Vakif University Faculty of Medicine, Gastroenterology, Istanbul, Turkey 3Marmara University School of Medicine, Gastroenterology, Istanbul, Turkey 4Kocaeli University Faculty of Medicine, Gastroenterology, Izmit, Turkey 5Istanbul University Istanbul Faculty of Medicine, Gastroenterology, Istanbul, Turkey 6Izmir Katip Celebi University, Gastroenterology, Izmir, Turkey 7Acıbadem Fulya Hospital, Gastroenterology, Istanbul, Turkey 8Ege University Medical School, Gastroenterology, Izmir, Turkey 9Mersin University Faculty of Medicine, Gastroenterology, Mersin, Turkey 10Dokuz Eylul University Faculty of Medicine, Gastroenterology, Izmir, Turkey 11Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey 12Trakya University Faculty of Medicine, Gastroenterology, Edirne, Turkey 13Baskent University Faculty of Medicine, Gastroenterology, Konya, Turkey 14Hacettepe University School of Medicine, Gastroenterology, Ankara, Turkey

P402: Discontinuation of short-term infliximab maintenance therapy in patients with Crohn's disease: outcomes and risk factors associated with relapseECCO '17 Barcelona
Year: 2017
Authors:

Zheng D.1, Mao R.1, Chen B.1, Feng T.1, Ben-Horin S.2, Chen M.*1

1The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China 2Tel-Aviv University, Tel-Aviv, Israel

P403: Golimumab therapy for ulcerative colitis – an Irish multicentre experienceECCO '17 Barcelona
Year: 2017
Authors:

O'Connell J.*1, Rowan C.2, Chan G.3, Harkin G.4, Parihar V.5, Layden J.3, Patchett S.5, Stack R.6, MacMathuna P.3, O'Toole A.5, Ryan B.7, MacCarthy F.1, McKiernan S.1, Doherty G.2, Eagan L.4, Kevans D.1

1St James Hospital, Gastroenterology, Dublin, Ireland 2St Vincent's University Hospital, Center for Colorectal Disease, Dublin, Ireland 3Mater Misericordiae University Hospital, Department of Gastroenterology, Dublin, Ireland 4University College Hospital Galway, Department of Gastroenterology, Galway, Ireland 5Beaumont Hospital, Department of Gastroeneterology, Dublin, Ireland 6Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Gastroenterology, Level 2, Dublin, Ireland 7Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Gastroenterology, Dublin, Ireland

P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD studyECCO '17 Barcelona
Year: 2017
Authors:

Martinelli M.*1, Strisciuglio C.2, Giugliano F.P.3, Urbonas V.4, Serban D.5, Banaszkiewicz A.6, Assa A.7, Drskova T.8, Hojsak I.9, Navas Lopez V.M.10, Romano C.11, Sladek M.12, Aloi M.13, Kucinskiene R.14, Staiano A.15, Miele E.15 ESPGHAN Open IBD Interest Group16

1University of Naples “Federico II”, Translational Medical Science, Section of Pediatrics, Naples, Italy 2Second University of Naples, Naples, Italy 3University of Naples, Naples, Italy 4Vilnius University Clinic of Children's Diseases, Vilnius University, Vilnius, Lithuania 5University of Medicine and Pharmacy Iuliu Hatieganu, Cluj–Napoca, Romania, Cluj Napoca, Romania 6Medical University of Warsaw, Paediatric Gastroenterology and Nutrition, Warsaw, Poland 7Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach-Tikva, Israel; and Sackler Faculty of Medicine, Tel-Aviv University,Tel Aviv, Israel 8Charles University, Prague, Czech Republic 9Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Zagreb, Croatia 10Hospital Materno Infantil, Avda. Arroyo de los ángeles s/n, 29011, Pediatric Gastroenterology and Nutrition Unit, Malaga, Spain 11University of Messina, Messina, Italy 12Department of Pediatrics, Gastroenterology and Nutrition Jagiellonian University School of Medicine, Cracow, Poland 13Sapienza University, Rome, Italy 14Department of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania 15University of Naples “Federico II”, Naples, Italy 16University of Naples, Translational Medical Science, Section of Pediatrics, Naples, Italy

P405: Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factorsECCO '17 Barcelona
Year: 2017
Authors:

Labidi A., Serghini M., Ben Mustapha N., Fekih M., Boubaker J., Filali A.

La Rabta University Hospital, Gastroenterology, Tunis, Tunisia

P406: Clinical correlations of infliximab trough levels and antibodies to infliximab in Korean patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Oh E.H.*1, Ko D.-H.2, Seo H.3, Chang K.3, Kim G.-U.3, Song E.M.3, Seo M.3, Lee H.-S.4, Hwang S.W.3,5, Yang D.-H.3, Ye B.D.3,5, Byeon J.-S.3, Myung S.-J.3, Yang S.-K.3,5, Park S.H.3,5

1University of Ulsan College of Medicine, Asan Medical Center, Department of Internal Medicine, Seoul, South Korea 2Hallym University College of Medicine, Dongtan Sacred Heart Hospital, Department of Laboratory Medicine, Hwaseong, South Korea 3University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea 4University of Ulsan College of Medicine, Asan Medical Center, Health Screening and Promotion Center, Seoul, South Korea 5Asan Medical Center, University of Ulsan College of Medicine, Inflammatory Bowel Disease Center, Seoul, South Korea

P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centreECCO '17 Barcelona
Year: 2017
Authors:

Orlandini B., Dragoni G., Bagnoli S., Deiana S., Macrì G., Rogai F.

Careggi, Gastroenterology, Florence, Italy

P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in NorwayECCO '17 Barcelona
Year: 2017
Authors:

Lerang F., Henriksen M., Jelsness-Jørgensen L.-P.

Central Hospital of Østfold, Medical, Sarpsborg, Norway